Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Exclusion Criteria

• •Symptomatic or actively progressing central nervous system (CNS) metastases
• •Spinal cord compression
• •Leptomeningeal disease
• •Uncontrolled pleural effusion, pericardial effusion, or ascites
• •Uncontrolled or symptomatic hypercalcemia
• •Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease, or current alcohol abuse
• •Malignancies other than SCLC within 5 years prior to randomization
• •Active or history of autoimmune disease or immune deficiencies
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computer Tomography (CT) scan
• •Known active tuberculosis, Current treatment with anti-viral therapy for HBV or HCV
• •Severe chronic or active infection
• •Treatment with therapeutic oral or IV antibiotics
• •Significant cardiovascular disease
• •Major surgical procedure other than for diagnosis
• •Prior allogeneic bone marrow transplantation or solid organ transplant
• •Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition
• •Administration of a live, attenuated vaccine
• •Prior treatment with CD137 agonists, T-cell co-stimulating, or immune checkpoint blockade therapies
• •Treatment with systemic immunostimulatory agents
• •Treatment with systemic immunosuppressive medications
• •History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
• •Known hypersensitivity to Chinese Hamster Ovary (CHO) cell products or to any component of the tiragolumab or atezolizumab formulations
• •History of allergic reactions to carboplatin or etoposide
• •Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab or within 90 days after the final dose of tiragolumab or for 6 months after the final dose of carboplatin or etoposide.